HIPK1: a New Druggable Kinase Target for Treating Pathological Cardiac Hypertrophy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HIPK1: a New Druggable Kinase Target for Treating Pathological Cardiac Hypertrophy

Published:2023-06-16 Issue: Volume: Page:
ISSN:1937-5387
Container-title:Journal of Cardiovascular Translational Research
language:en
Short-container-title:J. of Cardiovasc. Trans. Res.

Author:

Spanos Michail,Gokulnath Priyanka,Chatterjee Emeli,Varrias Dimitrios,Sun Lingfei,Das Saumya,Li Guoping^ORCID

Funder

National Center for Advancing Translational Sciences

American Heart Association

NIH

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Cardiology and Cardiovascular Medicine,Pharmaceutical Science,Genetics,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12265-023-10405-6.pdf

Reference5 articles.

1. Guerra FM, Gommerman JL, Corfe SA, Paige CJ, Rottapel R. Homeodomain-interacting protein kinase (HIPK)-1 is required for splenic B cell homeostasis and optimal T-independent type 2 humoral response. PLoS One. 2012;7(4):e35533. https://doi.org/10.1371/journal.pone.0035533.

2. Bei Y, Zhu Y, Wei M, et al. HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBPβ Axis. Adv Sci. 2023;e2300585. https://doi.org/10.1002/advs.202300585.

3. Li H, Trager LE, Liu X, et al. lncExACT1 and DCHS2 regulate physiological and pathological cardiac growth. Circulation. 2022;145(16):1218–33. https://doi.org/10.1161/CIRCULATIONAHA.121.056850.

4. Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48. https://doi.org/10.1186/s12943-018-0804-2.

5. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics — challenges and potential solutions. Nat Rev Drug Discov. 2021;20(8):629–51. https://doi.org/10.1038/s41573-021-00219-z.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3